PDL BioPharma, Inc. Derivative Instruments, Gain Recognized in Other Comprehensive Income (Loss), Effective Portion (Deprecated 2018-01-31)
PDL BioPharma, Inc. reported Derivative Instruments, Gain Recognized in Other Comprehensive Income (Loss), Effective Portion (Deprecated 2018-01-31) of $391.00 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2015-02-23.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainRecognizedInOtherComprehensiveIncomeEffectivePortion · last filed 2016-02-23
- PDL BioPharma, Inc. derivative instruments, gain recognized in other comprehensive income (loss), effective portion (deprecated 2018-01-31) for the quarter ending 2012-12-31 was $391.00K.
- PDL BioPharma, Inc. derivative instruments, gain recognized in other comprehensive income (loss), effective portion (deprecated 2018-01-31) for the quarter ending 2012-09-30 was $391.00K.
- PDL BioPharma, Inc. derivative instruments, gain recognized in other comprehensive income (loss), effective portion (deprecated 2018-01-31) for fiscal 2013 was $391.00K, a 0.00% change from fiscal 2012.
- PDL BioPharma, Inc. derivative instruments, gain recognized in other comprehensive income (loss), effective portion (deprecated 2018-01-31) for fiscal 2012 was $391.00K.
- PDL BioPharma, Inc. derivative instruments, gain recognized in other comprehensive income (loss), effective portion (deprecated 2018-01-31) for fiscal 2010 was $3.20M.
| Period end | Derivative Instruments, Gain Recognized in Other Comprehensive Income (Loss), Effective Portion (Deprecated 2018-01-31) 3 month | Derivative Instruments, Gain Recognized in Other Comprehensive Income (Loss), Effective Portion (Deprecated 2018-01-31) 6 month | Derivative Instruments, Gain Recognized in Other Comprehensive Income (Loss), Effective Portion (Deprecated 2018-01-31) 12 month |
|---|---|---|---|
| 2013-12-31 | $391.00K 10-K · filed 2015-02-23 | ||
| 2012-12-31 | $391.00K 10-Q · filed 2013-05-09 | $782.00K derived: sum of 2 quarters · filed 2016-02-23 | $391.00K 10-K · filed 2014-03-03 |
| 2012-09-30 | $391.00K 10-K · filed 2016-02-23 | ||
| 2010-12-31 | $3.20M 10-K · filed 2012-02-23 |